Amundi Has $1.82 Million Position in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Amundi significantly increased its stake in Collegium Pharmaceutical by 302.1%, owning approximately 62,592 shares valued at $1.82 million by the end of the first quarter.
• Collegium Pharmaceutical's board approved a $150 million share buyback plan, allowing the company to repurchase up to 15.4% of its outstanding shares, indicating confidence in its stock valuation.
• Several analysts upgraded Collegium Pharmaceutical, with a reported average target price of $42.33 and one analyst rating the stock as a "strong-buy."

Amundi increased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 302.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,592 shares of the specialty pharmaceutical company's stock after purchasing an additional 47,024 shares during the quarter. Amundi owned about 0.19% of Collegium Pharmaceutical worth $1,816,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of COLL. Wealthquest Corp bought a new position in Collegium Pharmaceutical in the first quarter valued at approximately $62,000. Virtus Fund Advisers LLC boosted its stake in Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 565 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Collegium Pharmaceutical in the first quarter valued at approximately $244,000. State of Wyoming boosted its stake in Collegium Pharmaceutical by 75.0% in the fourth quarter. State of Wyoming now owns 9,818 shares of the specialty pharmaceutical company's stock valued at $281,000 after acquiring an additional 4,208 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in Collegium Pharmaceutical by 4.5% in the first quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after acquiring an additional 477 shares during the last quarter.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 17,478 shares of the firm's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the sale, the executive vice president directly owned 70,264 shares in the company, valued at $2,699,542.88. This trade represents a 19.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John Gordon Freund sold 11,659 shares of the firm's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the sale, the director owned 23,129 shares in the company, valued at approximately $794,712.44. The trade was a 33.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,792 shares of company stock valued at $2,084,207. Insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Trading Up 1.7%

Shares of NASDAQ COLL traded up $0.62 during midday trading on Thursday, reaching $36.16. 214,456 shares of the stock were exchanged, compared to its average volume of 439,290. The business has a 50-day simple moving average of $35.29 and a two-hundred day simple moving average of $31.12. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 34.77 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10.

Collegium Pharmaceutical announced that its Board of Directors has approved a share repurchase program on Monday, July 7th that authorizes the company to buyback $150.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of recent research reports. Wall Street Zen raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. HC Wainwright raised shares of Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price objective on the stock in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $42.33.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.